Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 19/20 | 0.68 |
| ▸ | ALB | P02768 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20202167 | 0.95 | FOLH1 (0.63) | FOLH1ALB | |
| SCHEMBL20202217 | 0.94 | ALB (0.71) | FOLH1ALB | |
| SCHEMBL22488669 | 0.94 | ALB (0.69) | FOLH1ALB | |
| SCHEMBL22466348 | 0.94 | ALB (0.69) | FOLH1ALB | |
| SCHEMBL20202168 | 0.94 | ALB (0.74) | FOLH1ALB | |
| SCHEMBL18807597 | 0.91 | FOLH1 (0.79) | FOLH1 | |
| SCHEMBL18659693 | 0.91 | FOLH1 (0.79) | FOLH1 | |
| SCHEMBL1392836 | 0.91 | FOLH1 (0.79) | FOLH1 | |
| SCHEMBL19389387 | 0.91 | FOLH1 (0.79) | FOLH1 | |
| SCHEMBL418555 | 0.90 | FOLH1 (0.78) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11147889-B2 | Albumin-binding PSMA inhibitors | CANCER TARGETED TECHNOLOGY LLC (US) | 2021-10-19 | — | — | US | disclosed |
| US-20200061218-A1 | Albumin-Binding PSMA Inhibitors | CANCER TARGETED TECHNOLOGY LLC | 2020-02-27 | — | — | US | disclosed |
| WO-2018098390-A1 | ALBUMIN-BINDING PSMA INHIBITORS | CANCER TARGETED TECHNOLOGY LLC (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11147889-B2 | Albumin-binding PSMA inhibitors | PSMA1, ALB, PSMA2 | FOLH1 4/4885ALB 2/4885 |
| US-20200061218-A1 | Albumin-Binding PSMA Inhibitors | PSMA1, ALB, PSMA2 | FOLH1 4/4885ALB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.